Impact of COVID-19 Vaccine Type on the Efficacy and Safety of Nivolumab in Patients With Metastatic Non-small-cell Lung Cancer: A Multicenter Study.

With respect to subgroup analyses, a substantial proportion of patients with PD-L1 expression ≥50% had received both vaccine types, and in this subgroup, median PFS was numerically longer, although the difference did not reach statistical significance.

also in 111,027 other papers